Avenue Therapeutics, Inc. (NASDAQ:ATXI – Get Free Report) was the target of a significant decline in short interest in the month of March. As of March 31st, there was short interest totalling 283,100 shares, a decline of 9.7% from the March 15th total of 313,400 shares. Based on an average trading volume of 2,290,000 shares, the days-to-cover ratio is presently 0.1 days.
Avenue Therapeutics Trading Up 5.3 %
Shares of ATXI stock opened at $0.13 on Wednesday. Avenue Therapeutics has a 1 year low of $0.11 and a 1 year high of $1.28. The firm’s fifty day simple moving average is $0.15 and its 200 day simple moving average is $0.22. The firm has a market capitalization of $5.82 million, a P/E ratio of -0.10 and a beta of -0.24.
Avenue Therapeutics (NASDAQ:ATXI – Get Free Report) last announced its quarterly earnings results on Monday, March 18th. The company reported $0.56 earnings per share (EPS) for the quarter.
Institutional Investors Weigh In On Avenue Therapeutics
About Avenue Therapeutics
Avenue Therapeutics, Inc, a specialty pharmaceutical company, develops and commercializes therapies for the treatment of rare and neurologic diseases in the United States. Its lead product candidate includes AJ201, which in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous (IV) Tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.
See Also
- Five stocks we like better than Avenue Therapeutics
- How to Calculate Return on Investment (ROI)
- Silicon Motion Proves That AI in Motion Stays in Motion
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Undervalued UnitedHealth Group Won’t Be For Long
- The “How” and “Why” of Investing in 5G Stocks
- The 5 Stocks Most Sold By Insiders This Year
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.